What You Should Know:
– Causaly today announced Pipeline Graph, giving pharma research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery.
– The AI-powered application lets scientists proactively find and access competitive insights while they evaluate viable drug targets, helping them make confident pipeline decisions faster before investing in costly drug development programs.
Causaly Launches Pipeline Graph to Integrate Competitive Intelligence into AI-Driven Drug Discovery
Causaly, a leader in AI for life sciences, has announced Pipeline Graph, a new solution that embeds competitive intelligence directly into the drug discovery process. Building on the company’s advanced AI platform and recent innovations such as Causaly Discover and Causaly Deep Research, Pipeline Graph unifies scientific research and market insights into a single, AI-native application designed specifically for pharmaceutical scientists.
Unifying Competitive Intelligence and Biomedical Research
Pipeline Graph extends the capabilities of Causaly’s proprietary knowledge graph—which connects over 500 million facts and 100 million directional relationships, with more than 4 million new data points added monthly—by integrating competitive intelligence alongside biomedical data. This unified system:
· Allows scientists to access internal and external structured and unstructured data in one platform.
· Combines scientific literature, clinical trials, news, websites, and pipeline data to create a 360-degree view of the therapeutic landscape.
· Seamlessly integrates into researchers’ existing workflows, eliminating the need for multiple disconnected tools and extensive manual searches.
Addressing Industry Challenges
Today, pharmaceutical research teams face significant challenges in synthesizing fragmented competitive intelligence. Critical insights are often buried in emails, presentations, and static databases that lack real-time updates or comprehensive coverage—particularly for novel targets. Existing solutions typically fall short due to:
· Limited AI integration.
· Inadequate support for novel research areas.
· Manual processes that delay decision-making and slow the path to market.
Pipeline Graph resolves these pain points by offering a central, AI-native hub where researchers can rapidly connect the dots between early discovery, safety and efficacy data, and commercial strategy.
Yiannis Kiachopoulos, co-founder and CEO of Causaly, noted:
“The industry has been forced to settle for competitive intelligence products that lack AI innovation and require too much manual effort. Pipeline Graph brings competitive intelligence into the earliest phases of drug development, enabling faster, more informed decision-making.”
Expected Availability and Impact
Pipeline Graph is scheduled for release in July 2025. Already trusted by leading biopharmaceutical companies, Causaly’s platform empowers users to visualize, interpret, and automate research processes. With the launch of Pipeline Graph, Causaly strengthens its position as a critical enabler of end-to-end drug discovery and development—accelerating the journey of life-saving treatments to patients.
